Total Neoadjuvant Chemotherapy in Locally Advanced Gastric and Gastroesophageal Junction Cancer
Conditions: Gastric Cancer; Stomach Cancer; GastroEsophageal Cancer; Gastric Adenocarcinoma; Gastroesophageal Junction Adenocarcinoma; Advanced Gastric Adenocarcinoma; Gastric Neoplasm; Stomach Neoplasm; Gastrointestinal Cancer; Advanced Gastroesophageal Junction Ade nocarcinoma; Advanced Gastric Carcinoma Interventions: Drug: Docetaxel; Drug: Oxaliplatin; Drug: Leucovorin; Drug: Fluorouracil Sponsor: Ukrainian Society of Clinical Oncology Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 8, 2023 Category: Research Source Type: clinical trials
A Study of BGB-A445 in Combination With Other Investigational Agents in Participants With Non-Small Cell Lung Cancer
Condition: Non-Small Cell Lung Cancer Interventions: Drug: BGB-A445; Drug: Docetaxel; Drug: Tislelizumab; Drug: Sitravatinib; Drug: Ramucirumab; Drug: Selected Interventions; Drug: BGB-15025 Sponsor: BeiGene Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 8, 2023 Category: Research Source Type: clinical trials
Total Neoadjuvant Chemotherapy in Locally Advanced Gastric and Gastroesophageal Junction Cancer
Conditions: Gastric Cancer; Stomach Cancer; GastroEsophageal Cancer; Gastric Adenocarcinoma; Gastroesophageal Junction Adenocarcinoma; Advanced Gastric Adenocarcinoma; Gastric Neoplasm; Stomach Neoplasm; Gastrointestinal Cancer; Advanced Gastroesophageal Junction Ade nocarcinoma; Advanced Gastric Carcinoma Interventions: Drug: Docetaxel; Drug: Oxaliplatin; Drug: Leucovorin; Drug: Fluorouracil Sponsor: Ukrainian Society of Clinical Oncology Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 8, 2023 Category: Research Source Type: clinical trials
A Study of BGB-A445 in Combination With Other Investigational Agents in Participants With Non-Small Cell Lung Cancer
Condition: Non-Small Cell Lung Cancer Interventions: Drug: BGB-A445; Drug: Docetaxel; Drug: Tislelizumab; Drug: Sitravatinib; Drug: Ramucirumab; Drug: Selected Interventions; Drug: BGB-15025 Sponsor: BeiGene Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 8, 2023 Category: Research Source Type: clinical trials
Neoadjuvant Cadonilimab in Combination With Cisplatin and Nab-paclitaxel in Resectable Head and Neck Squamous Cell Carcinoma
Conditions: Head and Neck Squamous Cell Carcinoma; Locally Advanced Operable Interventions: Drug: Cadonilimab; Drug: Docetaxel; Drug: Cisplatin Sponsor: Xuekui Liu Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 5, 2023 Category: Research Source Type: clinical trials